Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The FDA's 2023 and 2024 actions against compounding pharmacies cited concerns about purity, potency, and sterility of BPC-157 products 3
Patients who notice no effect by day 7 are unlikely to benefit from continued injections without addressing other metabolic factors
REDEFINE 2 (combination, with type 2 diabetes) In adults with type 2 diabetes, the combination achieved 13.7% weight reduction versus 3.4% for placebo
Retatrutide has produced weight loss results that far exceed those of semaglutide (Ozempic), reducing weight by up to 24% in 48 weeks, compared to semaglutides 17.4% reduction after 68 weeks
Product Attributes CAS # : BPC-157: 137525-51-0
US$ 22.71
US$ 21.06
US$ 25.76
US$ 23.07
US$ 24.54
US$ 29.34
US$ 29.66
US$ 24.65
